Spiriva 18 mikrog Noorwegen - Noors - Statens legemiddelverk

spiriva 18 mikrog

orifarm as - tiotropiumbromid - inhalasjonspulver, hard kapsel - 18 mikrog

Spiriva 18 mikrog Noorwegen - Noors - Statens legemiddelverk

spiriva 18 mikrog

orifarm as - tiotropiumbromid - inhalasjonspulver, hard kapsel - 18 mikrog

Spiriva 18 mikrog Noorwegen - Noors - Statens legemiddelverk

spiriva 18 mikrog

orifarm as - tiotropiumbromid - inhalasjonspulver, hard kapsel - 18 mikrog

Spiriva 18 mikrog Noorwegen - Noors - Statens legemiddelverk

spiriva 18 mikrog

orifarm as - tiotropiumbromid - inhalasjonspulver, hard kapsel - 18 mikrog

Spiriva 18 mikrog Noorwegen - Noors - Statens legemiddelverk

spiriva 18 mikrog

orifarm as - tiotropiumbromid - inhalasjonspulver, hard kapsel - 18 mikrog

Spiriva 18 mikrog Noorwegen - Noors - Statens legemiddelverk

spiriva 18 mikrog

orifarm as - tiotropiumbromid - inhalasjonspulver, hard kapsel - 18 mikrog

Vamin 14 g N/L Elektrolyttfri Noorwegen - Noors - Statens legemiddelverk

vamin 14 g n/l elektrolyttfri

fresenius kabi norge as - halden - alanin / arginin / cystein / glutaminsyre / glysin / histidin / isoleucin / leucin / lysinacetat / metionin / fenylalanin / prolin / serin / treonin / tryptofan / tyrosin / valin / aspartinsyre - infusjonsvæske, oppløsning

Vamin 18 g N/L Elektrolyttfri Noorwegen - Noors - Statens legemiddelverk

vamin 18 g n/l elektrolyttfri

fresenius kabi norge as - halden - alanin / arginin / cystein / glutaminsyre / glysin / histidin / isoleucin / leucin / lysinacetat / metionin / fenylalanin / prolin / serin / treonin / tryptofan / tyrosin / valin / aspartinsyre - infusjonsvæske, oppløsning

Carmustine medac (previously Carmustine Obvius) Europese Unie - Noors - EMA (European Medicines Agency)

carmustine medac (previously carmustine obvius)

medac gesellschaft für klinische spezialpräparate mbh - carmustine - hodgkin disease; lymphoma, non-hodgkin - antineoplastiske midler - carmustine is indicated n adults in the following malignant neoplasms as a single agent or in combination with other antineoplastic agents and/or other therapeutic measures (radiotherapy, surgery): , brain tumours (glioblastoma, brain-stem gliomas, medulloblastoma, astrocytoma and ependymoma), brain metastases, secondary therapy in non-hodgkin’s lymphoma and hodgkin’s disease, as conditioning treatment prior to autologous haematopoietic progenitor cell transplantation (hpct) in malignant haematological diseases (hodgkin’s disease / non-hodgkin’s lymphoma).

Mepsevii Europese Unie - Noors - EMA (European Medicines Agency)

mepsevii

ultragenyx germany gmbh - vestronidase alfa - mucopolysaccharidosis vii - enzymer - mepsevii er angitt for behandling av ikke-nevrologiske manifestasjoner av mucopolysaccharidosis vii (mps vii; sly syndrom).